Glasdegib
- Generic Name
- Glasdegib
- Brand Names
- Daurismo
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22N6O
- CAS Number
- 1095173-27-5
- Unique Ingredient Identifier
- K673DMO5H9
- Background
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group...
- Indication
Glasdegib, in combination with cytarabine, is indicated for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are over 75 years old or that have co-morbidities that preclude intensive induction chemotherapy.
...
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
- Conditions
- Interventions
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT04842604
- Locations
- 🇦🇹
Landeskrankenhaus Salzburg, Universitatsklinik fur Innere Medizin III der PMU, Salzburg, Austria
🇭🇺Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Klinika, Hematologia Tanszek, Debrecen, Hungary
🇦🇹Uniklinikum Salzburg, Landeskrankenhaus Salzburg, Salzburg, Austria
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 30
- Registration Number
- NCT04231851
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
Acute Myeloid Leukemia Real World Treatment Patterns
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04230564
Glasdegib for Chronic Graft-Versus-Host Disease
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT04111497
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)
- Conditions
- Interventions
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- University Hospital Heidelberg
- Target Recruit Count
- 28
- Registration Number
- NCT04093505
- Locations
- 🇩🇪
University Hospital Heidelberg, Internal Medicine V, Heidelberg, Baden-Württemberg, Germany
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Yale University
- Target Recruit Count
- 1
- Registration Number
- NCT04051996
- Locations
- 🇺🇸
Yale Cancer Center/Smilow, New Haven, Connecticut, United States
Molecular Profiling of Advanced Soft-tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-04-10
- Target Recruit Count
- 603
- Registration Number
- NCT03784014
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷IUCT Oncopôle, Toulouse, France
🇫🇷Institut de Cancérologie de Montpellier, Montpellier, France
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 730
- Registration Number
- NCT03416179
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇵🇱WWCOiT im. M. Kopernika w Lodzi, Lodz, Poland
Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2022-03-17
- Target Recruit Count
- 21
- Registration Number
- NCT03415867
- Locations
- 🇪🇸
Hospital Clinic de Barcelona, Barcelona, Spain
🇪🇸Hospital General Universitario Morales Meseguer, Murcia, Spain
🇪🇸Hospital Universitario Son Espases, Palma de Mallorca, Spain
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03390296
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.